Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern

Neuroscience

Volumn 141, Issue 3, 2006, Pages 1149-1162

  Melnikova, T ^a   Savonenko, A ^a   Wang, Q ^a   Liang, X ^a   Hand, T ^a   Wu, L ^a   Kaufmann, W E ^a,b   Vehmas, A ^a   Andreasson, K I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

APPswe PS1dE9 mice; celecoxib; recognition memory; sex differences; spatial working memory; three trial Y maze

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PRESENILIN 1;

AGED; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; EXON; FEMALE; GENE DELETION; GENE OVEREXPRESSION; HYPERACTIVITY; INDUCED MUTATION; MALE; MAZE TEST; MEMORY DISORDER; MOLECULAR INTERACTION; MOUSE; MOUSE STRAIN; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN VARIANT; RECALL; RECOGNITION; SEX DIFFERENCE; SPATIAL MEMORY; SPECIES COMPARISON; TASK PERFORMANCE; TRANSGENE; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; COGNITION DISORDERS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; MALE; MAZE LEARNING; MEMBRANE PROTEINS; MEMORY, SHORT-TERM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PRESENILIN-1; PYRAZOLES; SEX CHARACTERISTICS; SULFONAMIDES;

EID: 33746433950     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.05.001     Document Type: Article

References (85)

1. Andersen K., Launer L.J., Dewey M.E., Letenneur L., Ott A., Copeland J.R., Dartigues J.F., Kragh-Sorensen P., Baldereschi M., Brayne C., Lobo A., Martinez-Lage J.M., Stijnen T., Hofman A., and EURODEM Incidence Research Group. Gender differences in the incidence of AD and vascular dementia. The EURODEM studies. Neurology 53 (1999) 1992-1997
2. Andreasson K.I., Savonenko A., Vidensky S., Goellner J.J., Zhang Y., Shaffer A., Kaufmann W.E., Worley P.F., Isakson P., and Markowska A.L. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 21 (2001) 8198-8209
3. Baker A.E., Brautigam V.M., and Watters J.J. Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor beta. Endocrinology 145 (2004) 5021-5032
4. Balboa M.A., Balsinde J., and Dennis E.A. Inflammatory activation of prostaglandin production by microglial cells antagonized by amyloid peptide. Biochem Biophys Res Commun 280 (2001) 558-560
5. Berger-Sweeney J., McPhie D.L., Arters J.A., Greenan J., Oster-Granite M.L., and Neve R.L. Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Brain Res Mol Brain Res 66 (1999) 150-162
6. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., and Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 56 (2004) 240-248
7. Borchelt D.R., Davis J., Fischer M., Lee M.K., Slunt H.H., Ratovitsky T., Regard J., Copeland N.G., Jenkins N.A., Sisodia S.S., and Price D.L. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 13 (1996) 159-163
8. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., and Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
9. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., and Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (1997) 939-945
10. Boutaud O., Andreasson K.I., Zagol-Ikapitte I., and Oates J.A. Cyclooxygenase-dependent lipid-modification of brain proteins. Brain Pathol 15 (2005) 139-142
11. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Pericak-Vance M.A., and Saunders A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16 (1995) 523-530
12. Cazevielle C., Muller A., Meynier F., Dutrait N., and Bonne C. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem Int 24 (1994) 156-159
13. Chen C., Magee J.C., and Bazan N.G. Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol 87 (2002) 2851-2857
14. Choi H.B., Khoo C., Ryu J.K., van Breemen E., Kim S.U., and McLarnon J.G. Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195. J Neurochem 83 (2002) 546-555
15. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5 (2004) 677-685
16. Cole G.M., Morihara T., Lim G.P., Yang F., Begum A., and Frautschy S.A. NSAID and antioxidant prevention of Alzheimer's disease. Lessons from in vitro and animal models. Ann N Y Acad Sci 1035 (2004) 68-84
17. Conrad C.D., Galea L.A., Kuroda Y., and McEwen B.S. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci 110 (1996) 1321-1334
18. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice. experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835 (1999) 18-26
19. Dellu F., Contarino A., Simon H., Koob G.F., and Gold L.H. Genetic differences in response to novelty and spatial memory using a two-trial recognition task in mice. Neurobiol Learn Mem 73 (2000) 31-48
20. Dellu F., Fauchey V., Le Moal M., and Simon H. Extension of a new two-trial memory task in the rat. influence of environmental context on recognition processes. Neurobiol Learn Mem 67 (1997) 112-120
21. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., and Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52 (2002) 771-778
22. Dumont M., Strazielle C., Staufenbiel M., and Lalonde R. Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation. Brain Res 1024 (2004) 113-121
23. Ennaceur A., and Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31 (1988) 47-59
24. Fitzpatrick A.L., Kuller L.H., Ives D.G., Lopez O.L., Jagust W., Breitner J.C., Jones B., Lyketsos C., and Dulberg C. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 52 (2004) 195-204
25. Gebhardt B.M., Varnell E.D., and Kaufman H.E. Inhibition of cyclooxygenase 2 synthesis suppresses herpes simplex virus type 1 reactivation. J Ocul Pharmacol Ther 21 (2005) 114-120
26. Hood W.F., Gierse J.K., Isakson P.C., Kiefer J.R., Kurumbail R.G., Seibert K., and Monahan J.B. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol 63 (2003) 870-877
27. Hoozemans J.J., Rozemuller A.J., Janssen I., De Groot C.J., Veerhuis R., and Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl) 101 (2001) 2-8
28. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
29. Hy L.X., and Keller D.M. Prevalence of AD among whites. a summary by levels of severity. Neurology 55 (2000) 198-204
30. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., and Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60 (2000) 5040-5044
31. Jankowsky J., Melnikova T., Fadale D., Xu G., Slunt H., Gonzales V., Younkin L., Younkin S., Borchelt D., and Savonenko A. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 62 (2005) 1220-1227
32. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., and Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo. evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13 (2004) 159-170
33. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., and Gordon M.N. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22 (2002) 2246-2254
34. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., and Isakson P. Cox-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A 93 (1996) 2317-2321
35. King D.L., and Arendash G.W. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75 (2002) 627-642
36. King D.L., Arendash G.W., Crawford F., Sterk T., Menendez J., and Mullan M.J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 103 (1999) 145-162
37. Koenigsknecht-Talboo J., and Landreth G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 25 (2005) 8240-8249
38. Kukar T., Murphy M.P., Eriksen J.L., Sagi S.A., Weggen S., Smith T.E., Ladd T., Khan M.A., Kache R., Beard J., Dodson M., Merit S., Ozols V.V., Anastasiadis P.Z., Das P., Fauq A., Koo E.H., and Golde T.E. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11 (2005) 545-550
39. Kulnane L.S., and Lamb B.T. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 8 (2001) 982-992
40. Lalonde R., Lewis T.L., Strazielle C., Kim H., and Fukuchi K. Transgenic mice expressing the betaAPP695SWE mutation. effects on exploratory activity, anxiety, and motor coordination. Brain Res 977 (2003) 38-45
41. Liang X., Wu L., Hand T., and Andreasson K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neurochem 92 (2005) 477-486
42. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., and Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20 (2000) 5709-5714
43. Liu D., Wu L., Breyer R., Mattson M.P., and Andreasson K. Neuroprotection by the PGE(2) EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 57 (2005) 758-761
44. Liu L., Ikonen S., Heikkinen T., Heikkila M., Puolivali J., van Groen T., and Tanila H. Effects of fimbria-fornix lesion and amyloid pathology on spatial learning and memory in transgenic APP+PS1 mice. Behav Brain Res 134 (2002) 433-445
45. Marriott L.K., Hauss-Wegrzyniak B., Benton R.S., Vraniak P.D., and Wenk G.L. Long-term estrogen therapy worsens the behavioral and neuropathological consequences of chronic brain inflammation. Behav Neurosci 116 (2002) 902-911
46. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R., and Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24 (2004) 257-268
47. McGeer E.G., and McGeer P.L. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. Biodrugs 19 (2005) 31-37
48. McGeer P.L., and McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22 (2001) 799-809
49. McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease. a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
50. McNay E.C., Fries T.M., and Gold P.E. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci U S A 97 (2000) 2881-2885
51. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., and Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57 (2000) 100-105
52. Montine T.J., Sidell K.R., Crews B.C., Markesbery W.R., Marnett L.J., Roberts II L.J., and Morrow J.D. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53 (1999) 1495-1498
53. Mouihate A., and Pittman Q.J. Neuroimmune response to endogenous and exogenous pyrogens is differently modulated by sex steroids. Endocrinology 144 (2003) 2454-2460
54. Nalbandian G., Paharkova-Vatchkova V., Mao A., Nale S., and Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol 175 (2005) 2666-2675
55. [No authors listed.] (1994) The Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ 150:899-913.
56. Nordell V.L., Lewis D.K., Bake S., and Sohrabji F. The neurotrophin receptor p75NTR mediates early anti-inflammatory effects of estrogen in the forebrain of young adult rats. BMC Neurosci 6 (2005) 58
57. Ognibene E., Middei S., Daniele S., Adriani W., Ghirardi O., Caprioli A., and Laviola G. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav Brain Res 156 (2005) 225-232
58. Pasinetti G.M., and Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87 (1998) 319-324
59. Sandberg G., Stewart W., Smialek J., and Troncoso J.C. The prevalence of the neuropathological lesions of Alzheimer's disease is independent of race and gender. Neurobiol Aging 22 (2001) 169-175
60. Sarter M., Bodewitz G., and Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl) 94 (1988) 491-495
61. Saukkonen K., Tomasetto C., Narko K., Rio M.C., and Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res 63 (2003) 3032-3036
62. Savonenko A.V., Xu G.M., Melnikova T., Morton G.L., Gonzales V., Wong M., Price D.L., Tang F., Markowska A.L., and Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Relationship to beta-amyloid and neurotransmitter abnormalities. Neurobiol Dis 18 (2005) 602-617
63. Savonenko A.V., Xu G.M., Price D.L., Borchelt D.R., and Markowska A.L. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol Dis 12 (2003) 194-211
64. Shie F.-S., Breyer R.M., and Montine T.J. Microglia lacking EP2 have enhanced Aβ phagocytosis yet lack Aβ-activated neurotoxicity. Am J Pathol 166 (2005) 1163-1172
65. Sisodia S.S., Martin L.J., Walker L.C., Borchelt D.R., and Price D.L. Cellular and molecular biology of Alzheimer's disease and animal models. Neuroimaging Clin N Am 5 (1995) 59-68
66. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95 (1998) 13313-13318
67. Soucy G., Boivin G., Labrie F., and Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J Immunol 174 (2005) 6391-6398
68. Stanton M.E., Thomas G.J., and Brito G.N. Posterodorsal septal lesions impair performance on both shift and stay working memory tasks. Behav Neurosci 98 (1984) 405-415
69. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
70. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., and Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. a systematic review. Neuroepidemiology 23 (2004) 159-169
71. Terry R.D., and Katzman R. Senile dementia of the Alzheimer type. Ann Neurol 14 (1983) 497-506
72. Tomassini V., Onesti E., Mainero C., Giugni E., Paolillo A., Salvetti M., Nicoletti F., and Pozzilli C. Sex hormones modulate brain damage in multiple sclerosis. MRI evidence. J Neurol Neurosurg Psychiatry 76 (2005) 272-275
73. Troncoso J.C., Cataldo A.M., Nixon R.A., Barnett J.L., Lee M.K., Checler F., Fowler D.R., Smialek J.E., Crain B., Martin L.J., and Kawas C.H. Neuropathology of preclinical and clinical late-onset Alzheimer's disease. Ann Neurol 43 (1998) 673-676
74. Vidensky S., Zhang Y., Hand T., Goellner J., Shaffer A., Isakson P., and Andreasson K. Neuronal overexpression of COX-2 results in dominant production of PGE2 and altered fever response. Neuromol Med 3 (2003) 15-28
75. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
76. Weggen S., Eriksen J.L., Sagi S.A., Pietrzik C.U., Ozols V., Fauq A., Golde T.E., and Koo E.H. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278 (2003) 31831-31837
77. West M.J., Slomianka L., and Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231 (1991) 482-497
78. Whitehouse P.J., Struble R.G., Hedreen J.C., Clark A.W., and Price D.L. Alzheimer's disease and related dementias. selective involvement of specific neuronal systems. CRC Crit Rev Clin Neurobiol 1 (1985) 319-339
79. Wunderlich F., Benten W.P., Lieberherr M., Guo Z., Stamm O., Wrehlke C., Sekeris C.E., and Mossmann H. Testosterone signaling in T cells and macrophages. Steroids 67 (2002) 535-538
80. Xiang Z., Ho L., Valdellon J., Borchelt D., Kelley K., Spielman L., Aisen P.S., and Pasinetti G.M. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 23 (2002) 327-334
81. Xiang Z., Ho L., Yemul S., Zhao Z., Qing W., Pompl P., Kelley K., Dang A., Teplow D., and Pasinetti G.M. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr 10 (2002) 271-278
82. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., and Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons. regulation by synaptic activity and glucocorticoids. Neuron 11 (1993) 371-386
83. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., and Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23 (2003) 7504-7509
84. Zagol-Ikapitte I., Masterson T.S., Amarnath V., Montine T.J., Andreasson K.I., Boutaud O., and Oates J.A. Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem 94 (2005) 1140-1145
85. Zandi P.P., and Breitner J.C. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 22 (2001) 811-817